Table 1.
Baseline demographics and changes of parameter of Parkinson's disease characteristics and the change from baseline to 16th week
| Placebo group (n = 8) | Hydrogen gas group (n = 7) | Mann–Whitney U test p | ||
|---|---|---|---|---|
| Modified Hohen and Yahr stage | Mean (SD) | 2.5 (0.5) | 2.0 (0.6) | > 0.05 |
| Age | Mean (SD) | 66.4 (10.3) | 65.9 (9.4) | > 0.05 |
| Male: female | n | 3:5 | 7:0 | |
| Onset age | Mean (SD) | 56.8 (11.8) | 56.7 (8.7) | > 0.05 |
| Disease duration (years) | Mean (SD) | 10.0 (6.9) | 9.1 (7.1) | > 0.05 |
| Levodopa (mg) | Mean (SD) | 431.3 (192.7) | 371.4 (256.3) | > 0.05 |
| Wearing off + | n | 3 | 1 | |
|
MDS-UPDRS Total |
Mean (SD) | 47.8 (23.9) | 34.9 (18.6) | > 0.05 |
| Part I | Mean (SD) | 7.6 (4.6) | 5.4 (2.1) | > 0.05 |
| Part II | Mean (SD) | 9.8 (6.5) | 5.9 (5.6) | > 0.05 |
| Part III | Mean (SD) | 28.8 (14.8) | 22.0 (10.6) | > 0.05 |
| Part IV | Mean (SD) | 1.6 (2.1) | 1.6 (2.8) | > 0.05 |
| PDQ-39 | Mean (SD) | 48.9 (25.9) | 22.4 (19.9) | 0.021 |
| Urine N1,N8-diacetylspermidine (ng/mgCr) | Mean (SD) | 9.4 (3.0) | 9.4 (2.4) | > 0.05 |
| N1,N8-diacetylspermidine (pmol/100 µl serum) | Mean (SD) | 0.38(0.16) | 0.31(0.06) | > 0.05 |
|
Inhalation time Hours |
mean (SD) | 203.1 (23.0) | 185.0 (26.1) | > 0.05 |
| Change from the baseline to the 16th Week | ||||
|
MDS-UPDRS Total |
Mean (SD) | 0.8 (10.3) | 1.9 (13.1) | > 0.05 |
| Part I | Mean (SD) | 0.0 (3.8) | -0.1 (2.8) | > 0.05 |
| Part II | Mean (SD) | 0.9 (2.1) | 2.4 (4.0) | > 0.05 |
| Part III | Mean (SD) | –1.8 (4.7) | 3.0 (9.0) | > 0.05 |
| PDQ-39 | Mean (SD) | –6.9 (24.7) | 4.9 (8.7) | > 0.05 |
| Urine 8-hydroxy-2-deoxyguanosine (ng/mgCr) | Mean (SD) | –0.3 (4.8) | 0.4 (2.1) | > 0.05 |
| N1,N8-diacetylspermidine (pmol/100 µl serum) | Mean (SD) | -0.01(0.08) | 0.04(0.08) | > 0.05 |
MDS-UPDRS Movement Disorder Society Unified Parkinson’s disease rating scale, PDQ-39 Parkinson’s disease Questionnaire-39